Literature DB >> 30888972

Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease.

Tawfik Khoury1,2,3, Amir Mari1,3, Wiliam Nseir4, Anas Kadah2,3, Wisam Sbeit2,3, Mahmud Mahamid1,3.   

Abstract

BACKGROUND AND AIM: The progression of nonalcoholic fatty liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) is believed to be the driver for future development of fibrosis and cirrhosis. Nevertheless, there remains a lack of noninvasive methods for the diagnosis of NASH. The aim of the present study was to determine the role of neutrophil-to-lymphocyte ratio (NLR) in predicting histological severity in NAFLD. PATIENTS AND METHODS: We performed a single-center retrospective study in EMMS Nazareth Hospital from July 2014 to May 2017. Liver biopsies were evaluated using the steatosis, activity, and fibrosis scoring system, which includes three components: (i) steatosis (0-3), (ii) activity grade (0-4), and (iii) fibrosis (0-4). Patients were divided into two groups. The first group was considered to have NAFLD when fibrosis grade was 0-1 and inflammatory activity was 0-1, whereas the second group included patients with fibrosis grade of 2-4 and inflammatory activity grade of 2-3, considered to have NASH.
RESULTS: Ninety-one (91) patients with biopsy-proven fatty liver were included. The average age was 42.13 ± 11.5 (18-74) years. Fifty-seven (62.6%) patients were male. Univariate analysis revealed several factors to be associated with advanced fibrosis and inflammatory activity, including NLR, C-reactive protein, and HOMA-IR, which correlated with fibrosis [odds ratio (OR): 1.405, 95% confidence interval (CI): 1.21-1.63, P < 0.0001; OR: 1.329, 95% CI: 1.05-1.68, P = 0.016; and OR: 1.922, 95% CI: 1.18-3.11, P = 0.007, respectively], and NLR, triglycerides, and HOMA-IR, which correlated with hepatocyte inflammation (OR: 1.210, 95% CI: 1.08-1.35, P = 0.0009; OR: 0.984, 95% CI: 0.97-0.99, P = 0.01; and OR: 2.069, 95% CI: 1.28-3.34, P = 0.003, respectively). On multivariate logistic regression analysis, NLR remains independently associated with advanced fibrosis grade and inflammatory activity (OR: 0.734, 95% CI: 0.631-0.854, P < 0.0001, area under the curve: 0.8622 and OR: 0.836, 95% CI: 0.74-0.95, P = 0.006, area under the curve: 0.7845, respectively). Our second major finding was defining an NLR cut-off point that was associated with inflammatory activity and fibrosis grade using receiver operating characteristic analysis based on the Youden index (J), which is defined by the maximal sensitivity and specificity.
CONCLUSION: NLR showed significant independent correlation with advanced inflammation and fibrosis in patients with NAFLD. This simple available laboratory tool may be incorporated into future diagnostic scores.

Entities:  

Year:  2019        PMID: 30888972     DOI: 10.1097/MEG.0000000000001393

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  14 in total

Review 1.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

2.  Liver stiffness measurement identifies subclinical myocardial dysfunction in non-advanced non-alcoholic fatty liver disease patients without overt heart disease.

Authors:  Andrea Sonaglioni; Federica Cerini; Antonio Cerrone; Lorenzo Argiento; Gian Luigi Nicolosi; Elisabetta Rigamonti; Michele Lombardo; Maria Grazia Rumi; Mauro Viganò
Journal:  Intern Emerg Med       Date:  2022-03-17       Impact factor: 5.472

3.  Association Between Neutrophil-to-Lymphocyte Ratio with Inflammatory Activity and Fibrosis in Non-alcoholic Fatty Liver Disease.

Authors:  Jin WenYi; Qian Ting; Ying PiaoPiao; Wu JinMing
Journal:  Turk J Gastroenterol       Date:  2022-01       Impact factor: 1.555

Review 4.  A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix.

Authors:  Mengting Zhou; Naihua Hu; Meichen Liu; Ying Deng; Linfeng He; Chaocheng Guo; Xingtao Zhao; Yunxia Li
Journal:  Biomed Res Int       Date:  2020-04-20       Impact factor: 3.411

Review 5.  Immunological mechanisms and therapeutic targets of fatty liver diseases.

Authors:  Hua Wang; Wajahat Mehal; Laura E Nagy; Yaron Rotman
Journal:  Cell Mol Immunol       Date:  2020-12-02       Impact factor: 11.530

Review 6.  The Roles of Neutrophils in the Pathogenesis of Liver Diseases.

Authors:  Jiaojiao Tang; Zijun Yan; Qiyu Feng; Lexing Yu; Hongyang Wang
Journal:  Front Immunol       Date:  2021-03-08       Impact factor: 7.561

7.  Prognostic Nomogram for Patients with Hepatitis E Virus-related Acute Liver Failure: A Multicenter Study in China.

Authors:  Jian Wu; Cuifen Shi; Xinyu Sheng; Yanping Xu; Jinrong Zhang; Xinguo Zhao; Jiong Yu; Xinhui Shi; Gongqi Li; Hongcui Cao; Lanjuan Li
Journal:  J Clin Transl Hepatol       Date:  2021-05-06

8.  Increased neutrophil-to-lymphocyte ratio predicts the development of post-stroke infections in patients with acute ischemic stroke.

Authors:  Lanying He; Jian Wang; Feng Wang; Lili Zhang; Lijuan Zhang; Wang Zhao
Journal:  BMC Neurol       Date:  2020-09-01       Impact factor: 2.474

9.  Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.

Authors:  Ayman Bannaga; Ramesh P Arasaradnam
Journal:  World J Gastroenterol       Date:  2020-09-07       Impact factor: 5.742

Review 10.  Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.

Authors:  Alvaro Santos-Laso; María Gutiérrez-Larrañaga; Marta Alonso-Peña; Juan M Medina; Paula Iruzubieta; María Teresa Arias-Loste; Marcos López-Hoyos; Javier Crespo
Journal:  Biomedicines       Date:  2021-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.